Key result
Novel transcatheter mitral repair and replacement expand treatment options beyond anatomically restricted M-TEER.
Answers are grounded in this paper and cite their sources.
This review summarizes emerging percutaneous mitral valve therapies—including TMVR, transcatheter annuloplasty, and chordal/leaflet-based technologies—that aim to address the anatomical limitations and residual MR associated with M-TEER.
Mitral regurgitation (MR) is one of the most prevalent valvular heart diseases worldwide. Mitral transcatheter edge-to-edge repair (M-TEER) has become the cornerstone percutaneous treatment for both primary and secondary MR; however, its efficacy remains highly anatomy-dependent, with a substantial proportion of patients deemed unsuitable and others experiencing residual or recurrent MR at follow-up. Looking beyond M-TEER, a growing armamentarium of alternative transcatheter strategies has emerged, including transcatheter mitral valve replacement (TMVR) platforms direct and indirect annuloplasty systems, and, more recently, percutaneous chordal replacement/leaflet-based technologies. This review discusses the current evidence supporting TMVR, transcatheter annuloplasty, and emerging leaflet-based strategies, focusing on those technologies most likely to redefine the treatment algorithm for mitral regurgitation over the coming years.
No takes yet. Share an insight, caveat, or question.
Pensotti et al. (2026) conducted a review in Mitral regurgitation. Transcatheter mitral valve replacement (TMVR), transcatheter annuloplasty, and percutaneous chordal replacement/leaflet-based technologies vs. Mitral transcatheter edge-to-edge repair (M-TEER) was evaluated. Alternative transcatheter strategies including TMVR, annuloplasty, and chordal replacement are emerging to treat mitral regurgitation beyond anatomy-dependent M-TEER.
Synapse has enriched 10 related papers. Consider them for comparative context: